Clinical Trial Detail

NCT ID NCT03094052
Title Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Neratinib, With or Without Trastuzumab
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of California, San Francisco
Indications

breast adenocarcinoma

Therapies

Neratinib

Loperamide

Crofelemer

Neratinib + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST